<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03424850</url>
  </required_header>
  <id_info>
    <org_study_id>201801118</org_study_id>
    <nct_id>NCT03424850</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy</brief_title>
  <official_title>A Phase I/II Dose-escalation Study Evaluating the Safety and Efficacy of 21 Gy, 23 Gy and 25 Gy for High Dose Rate (HDR) Prostate Brachytherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to learn more about the outcomes and early and late&#xD;
      side effects of treating early stage prostate cancer with high dose rate brachytherapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2018</start_date>
  <completion_date type="Anticipated">February 27, 2028</completion_date>
  <primary_completion_date type="Anticipated">February 27, 2028</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical control experienced by patients with prostate cancer treated with an HDR implant</measure>
    <time_frame>Through 3 years after implant</time_frame>
    <description>-Response will be determined by PSA. The Phoenix definition will be used for determining biochemical failure: a rise of 2 ng/mL or more above the PSA nadir</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of acute toxicity experienced by patients with prostate cancer treated with an HDR implant</measure>
    <time_frame>Through 3 years after implant</time_frame>
    <description>-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of late toxicity experienced by patients with prostate cancer treated with an HDR implant</measure>
    <time_frame>Through 3 years after implant</time_frame>
    <description>-The descriptions and grading scales found in the revised NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 will be utilized for all toxicity reporting.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Optimal dose of radiation</measure>
    <time_frame>Through 3 months after completion of implant for all patients enrolled (estimated to be 5 years and 3 months)</time_frame>
    <description>-The optimal dose is defined as the dose level immediately below the dose level at which 2 patients of a cohort (of 2 to 6 patients) experience dose-limiting toxicity within the DLT assessment period (3 months after implant) OR the maximally administered dose if fewer than 2 patients in that cohort experience DLT.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Prostate Neoplasm</condition>
  <arm_group>
    <arm_group_label>HDR brachytherapy - 21 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 21 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDR brachytherapy - 23 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 23 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HDR brachytherapy - 25 Gy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>-All patients will be treated with a single implant and single HDR fraction. Treatment will be delivered within a single 24-hour period measured from the beginning of the implant procedure. All patients will receive a dose of 25 Gy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>HDR brachytherapy</intervention_name>
    <description>Dose constraints for 21 Gy:&#xD;
Bladder and rectum: V70 &lt; 1 cc&#xD;
Urethra: V115 &lt; 1 cc&#xD;
V135: 0%&#xD;
Dose constraints for 23 Gy:&#xD;
Bladder and rectum: V65 &lt; 1 cc&#xD;
Urethra: V105 &lt; 1 cc&#xD;
V125: 0%&#xD;
Dose constraints for 25 Gy:&#xD;
Prostate V100 &gt;90% (&gt;95% preferred)&#xD;
Bladder and rectum: V70 &lt; 1 cc, Dmax &lt;115%&#xD;
Urethra: V110 &lt; 1 cc, Dmax &lt;120%</description>
    <arm_group_label>HDR brachytherapy - 21 Gy</arm_group_label>
    <arm_group_label>HDR brachytherapy - 23 Gy</arm_group_label>
    <arm_group_label>HDR brachytherapy - 25 Gy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed diagnosis of early stage prostate cancer.&#xD;
&#xD;
          -  Must be considered either low-risk (T1-T2a, Gleason ≤ 6, PSA &lt; 10 ng/mL) or favorable&#xD;
             intermediate-risk (Gleason 3 +4 = 7, percentage of positive biopsy cores &lt; 50%, no&#xD;
             more than one NCCN intermediate risk factor).&#xD;
&#xD;
          -  Prior androgen deprivation therapy is allowed and may have been initiated up to 6&#xD;
             months prior to the date of the HDR implant. The complete duration of androgen&#xD;
             deprivation therapy can range from 4 months to 36 months provided it has been&#xD;
             initiated no more than 6 months prior to the date of the HDR implant.&#xD;
&#xD;
          -  At least 18 years of age.&#xD;
&#xD;
          -  ECOG performance status ≤ 2&#xD;
&#xD;
          -  Able to understand and willing to sign an IRB approved written informed consent&#xD;
             document (or that of legally authorized representative, if applicable).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior radiation therapy to the prostate or lower pelvis encompassing the prostate.&#xD;
&#xD;
          -  A history of other malignancy ≤ 5 years previous with the exception of basal cell or&#xD;
             squamous cell carcinoma of the skin which were treated with local resection only.&#xD;
&#xD;
          -  Currently receiving any other investigational agents.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac&#xD;
             arrhythmia.&#xD;
&#xD;
          -  Unable to undergo general, spinal or local anesthesia.&#xD;
&#xD;
          -  Prior TURP&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiram A Gay, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hiram A Gay, M.D.</last_name>
    <phone>314-362-8516</phone>
    <email>hiramgay@wustl.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiram A Gay, M.D.</last_name>
      <phone>314-362-8516</phone>
      <email>hiramgay@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Hiram A Gay, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeff M Michalski, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brian Baumann, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Randall Brenneman, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joshua Schiff, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yi Huang</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Altman, Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 31, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 7, 2018</study_first_posted>
  <last_update_submitted>September 1, 2021</last_update_submitted>
  <last_update_submitted_qc>September 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

